Merck Swings To Quarterly Loss On Cidara Deal - Merck & Co (NYSE:MRK)

Merck Swings To Quarterly Loss On Cidara Deal - Merck & Co (NYSE:MRK)

Merck & Co. Inc. (NYSE:MRK) on Thursday reported its first-quarter 2026 financial results, which highlighted sales growth driven by continued strength in oncology and animal health. Merck Q1 Earnings Key Takeaways Merck reported a first-quarter adjusted loss of $1.28, better than the analyst expectation of a loss of $1.51, down from earnings of $2.22 per share a year ago due to a charge for the acquisition of Cidara Therapeutics of $3.62 per sha…

Merck beats earnings estimates as cancer drug Keytruda sales surged 12%

The drugmaker posted $16.29 billion in quarterly revenue, topping Wall Street forecasts, though a big acquisition charge pushed it to a net loss

Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook

Merck narrowed its 2026 sales guidance and hiked its adjusted profit outlook.

Merck Q1 2026 Earnings Report Review - PressReach

Merck & Co. (NYSE:MRK) has released its financial results for the first quarter of 2026, showcasing a robust performance driven by strategic initiatives and strong market demand for its products. The pharmaceutical giant reported a significant increase in revenue, attributed largely to the sales of its blockbuster drug, Keytruda, which continues to be a major contributor to the company’s earnings. Keytruda, a leading cancer therapy, has consiste…